The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen

Transfusion

Volumn 42, Issue 9, 2002, Pages 1159-1172

  Menéndez, Pablo ^a,b,c,d,e   Caballero, Maria D ^a,b,c,d,e   Prosper, Felipe ^a,b,c,d,e   Del Cañizo, Maria C ^a,b,c,d,e   Pérez Simón, Jose A ^a,b,c,d,e   Mateos, Maria V ^a,b,c,d,e   Nieto, Maria J ^a,b,c,d,e   Corral, Mercedes ^a,b,c,d,e   Romero, Mercedes ^a,b,c,d,e   García Conde, Javier ^a,b,c,d,e   Montalbán, Maria A ^a,b,c,d,e   Miguel, Jesus F  San ^a,b,c,d,e   Orfao, Alberto ^a,b,c,d,e  

^a Centro de Investigacion del Cancer   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

ADULT; ARTICLE; BLOOD; BONE MARROW CELL; BREAST TUMOR; CELL DIFFERENTIATION; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; GERM CELL TUMOR; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION; LEUKAPHERESIS; LEUKOCYTE; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NEOPLASM; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; STEM CELL MOBILIZATION; THROMBOCYTE;

ADULT; ANTIGENS, CD34; BLOOD PLATELETS; BONE MARROW CELLS; BREAST NEOPLASMS; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GERMINOMA; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; INFECTION; LEUKAPHERESIS; LEUKOCYTE COUNT; LEUKOCYTES; LYMPHOCYTES; MALE; MULTIPLE MYELOMA; NEOPLASMS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; STEM CELL FACTOR;

EID: 18744388376     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2002.00190.x     Document Type: Article

References (47)

1. 1 Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor‐cell mobilization after low‐dose cyclophosphamide and granulocyte colony‐stimulating factor: an analysis of progenitor‐cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997 ; 15: 535 ‐ 46.
2. 2 Demirer T, Buckner CD, Storer B, et al. Effect of different chemotherapy regimens on peripheral‐blood stem‐cell collections in patients with breast cancer receiving granulocyte colony‐stimulating factor. J Clin Oncol 1997 ; 15: 684 ‐ 90.
3. 3 Hong DS, Deeg HJ. Hemopoietic stem cells: sources and applications. Med Oncol 1994 ; 11: 63 ‐ 8.
4. 4 Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997 ; 126: 600 ‐ 7.
5. 5 To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992 ; 9: 277 ‐ 84.
6. 6 Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high‐dose cyclophosphamide‐treated patients: enhancement by intravenous recombinant human granulocyte‐macrophage colony‐stimulating factor. Blood 1989 ; 74: 1905 ‐ 14.
7. 7 Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991 ; 77: 400 ‐ 9.
8. 8 Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992 ; 1: 329 ‐ 41.
9. 9 Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma. identification of favorable variables for rapid engraftment in 225 patients. Blood 1995 ; 85: 588 ‐ 96.
10. 10 Meldgaard Knudsen L, Jensen L, Jarlbaek L, et al. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica 1999 ; 84: 517 ‐ 24.
11. 11 Gertz MA, Lacy MQ, Inwards DJ, et al. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1997 ; 20: 375 ‐ 80.
12. 12 Bolwell B, Goormastic M, Andresen S, et al. Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998 ; 22: 547 ‐ 51.
13. 13 Menendez P, Del Canizo MC, Orfao, A. Immunophenotypic characteristics of PB‐mobilised CD34+ hematopoietic progenitor cells. J Biol Regul Homeost Agents 2001 ; 15: 53 ‐ 61.
14. 14 Brendel C, Neubauer A. Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. Leukemia 2000 ; 14: 1711 ‐ 17.
15. 15 Menendez P, Prosper F, Bueno C, et al. Sequential analysis of CD34+ and CD34–cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G–CSF and cyclophosphamide. Leukemia 2000 ; 15: 430 ‐ 9.
16. 16 Pecora AL, Preti RA, Gleim GW, et al. CD34+CD33‐ cells influence days to engraftment and transfusion requirements in autologous blood stem‐cell recipients. J Clin Oncol 1998 ; 16: 2093 ‐ 104.
17. 17 Dercksen MW, Rodenhuis S, Dirkson MK, et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral‐blood stem‐cell transplantation. J Clin Oncol 1995 ; 13: 1922 ‐ 32.
18. 18 Copelan EA, Ceselski SK, Ezzone SA, et al. Mobilization of peripheral‐blood progenitor cells with high dose etoposide and granulocyte colony‐stimulating factor in patients with breast cancer, non‐Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997 ; 15: 759 ‐ 65.
19. 19 Weaver A, Ryder D, Crowther D, et al. Increased numbers of long‐term culture‐initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony‐stimulating factor. Blood 1996 ; 88: 3323 ‐ 8.
20. 20 Gazitt Y. Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors. Stem Cells 2000 ; 18: 390 ‐ 8.
21. 21 Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous hematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001 ; 27: 463 ‐ 70.
22. 22 Gratama JW, Keeney M, Sutherland DR. Enumeration of CD34+ hematopoietic stem and progenitor cells. Curr Protocols Cytometry 1999:6.4.1‐22.
23. 23 Gratama JW, Menendez P, Kraan J, Orfao A. Loss of CD34+ hematopoietic progenitor cells due to washing can be reduced by the use of fixative‐free erythrocyte lysing reagents. J Immunol Methods 2000 ; 239: 13 ‐ 21.
24. 24 Menendez P, Redondo O, Rodriguez A, et al. Comparison between a lyse‐and then‐wash method and a lyse‐non‐wash technique for the enumeration of CD34+ hematopoietic progenitor cells. Cytometry 1998 ; 34: 264 ‐ 71.
25. 25 Kappelmayer J, Gratama JW, Karaszi E, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a: interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods 2000 ; 242: 53 ‐ 65.
26. 26 Perez‐Simon JA, Martin A, Caballero D, et al. Clinical significance of CD34+ cell dose in long‐term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 ; 24: 1279 ‐ 83.
27. 27 Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG–CSF). an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994 ; 87: 825 ‐ 31.
28. 28 Gratama JW, Orfao A, Barnett D, et al. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. Cytometry 1998 ; 34: 128 ‐ 42.
29. 29 To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997 ; 89: 2233 ‐ 58.
30. 30 Knudsen LM, Gaarsdal E, Jensen L, et al. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. J Hematother 1996 ; 5: 399 ‐ 406.
31. 31 Weaver A, Chang J, Wrigley E, et al. Randomized comparison of progenitor‐cell mobilization using chemotherapy, stem‐cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 1998 ; 16: 2601 ‐ 12.
32. 32 Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization by stem cell factor and filgrastim in high‐risk breast cancer patients. Blood 1999 ; 93: 2491 ‐ 501.
33. 33 Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998 ; 4: 311 ‐ 6.
34. 34 Begley CG, Basser R, Mansfield R, et al. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony‐stimulating factor to humans. Blood 1997 ; 90: 3378 ‐ 89.
35. 35 Basser RL, To LB, Begley CG, et al. Rapid hematopoietic recovery after multicycle high‐dose chemotherapy. enhancement of filgrastim‐induced progenitor‐cell mobilization by recombinant human stem‐cell factor. J Clin Oncol 1998 ; 16: 1899 ‐ 908.
36. 36 Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997 ; 90: 2939 ‐ 51.
37. 37 Shpall EJ. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999 ; 2 (Suppl): S13 ‐ 9.
38. 38 Ho AD, Young D, Maruyama M, et al. Pluripotent and lineage‐committed CD34+ subsets in leukapheresis products mobilized by G–CSF, GM‐CSF vs. a combination of both. Exp Hematol 1996 ; 24: 1460 ‐ 8.
39. 39 Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) or G–CSF. potential role in allogeneic marrow transplantation. Blood 1995 ; 85: 275 ‐ 82.
40. 40 Mohle R, Pforsich M, Fruehauf S, et al. Filgrastim post‐chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady‐state hematopoiesis. Bone Marrow Transplant 1994 ; 14: 827 ‐ 32.
41. 41 Weaver A, Ryder D, Crowther D, et al. Increased numbers of long‐term culture‐initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony‐stimulating factor. Blood 1996 ; 88: 3323 ‐ 8.
42. 42 McLeod BC, Price TH, Drew MJ. Apheresis: principles and practice. Bethesda, MD: American Association of Blood Banks; 1997.
43. 43 Stiff P, Gingrich R, Luger S, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non‐Hodgkin's lymphoma. Bone Marrow Transplant 2000 ; 26: 471 ‐ 81.
44. 44 Buscemi F, Indovina A, Scime R, et al. CD34+ cell subsets and platelet recovery after PBPC autograft. Bone Marrow Transplant 1995 ; 16: 855 ‐ 6.
45. 45 Chandrasekar PH, Abraham OC, Klein J, et al. Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. Clin Infect Dis 2001 ; 32: 546 ‐ 51.
46. 46 Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001 ; 32: 391 ‐ 5.
47. 47 Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992 ; 165: 352 ‐ 63.